Practice Focus


Hon. William B. Bryant, U.S. District Court for the District of Columbia


University of Virginia School of Law, J.D., 1974

Yale University, B.A., 1970

Photo of William B. Schultz

William B. Schultz


William B. Schultz represents healthcare consumers, payers and providers with complex regulatory issues before the U.S. Department of Health and Human Services (HHS), other federal agencies, and the courts. He also assists generic drug companies, nonprofit organizations and other clients with matters before the Food and Drug Administration (FDA) and the courts.

Bill served as General Counsel of HHS from March 2011 to June 2016, where he was legal counsel to two HHS secretaries on all legal matters and managed an office of 500 lawyers across 8 offices, covering 10 regions across the country. HHS administers $1 trillion per year in federal programs, including Medicare, Medicaid, the Affordable Care Act, the FDA, the National Institutes of Health, and the Centers for Disease Control. The office of general counsel is responsible for all litigation where HHS is a party, ensuring regulations and policy decisions are consistent with the law, reviewing legal issues involving appropriations, and ensuring ethical rules are followed.

Prior to joining HHS, Bill was a partner at the Zuckerman Spaeder and represented nonprofit organizations, state and local governments, individuals, generic drug companies and small biotechnology companies.

From 1999 to 2000, Bill was deputy assistant attorney general at the U.S. Department of Justice, where he was responsible for overseeing all civil division appellate litigation and the department’s tobacco litigation team.

From 1994 to 1999, Bill was deputy commissioner for policy for the FDA, where he was the principal advisor to the Commissioner on all significant policy issues and was responsible for development and management of all regulations.

From 1989 to 1994, Bill was the counsel to the Subcommittee on Health and the Environment (Rep. Henry A. Waxman, chairman), Committee on Energy and Commerce, U.S. House of Representatives, where he worked on healthcare, FDA, tobacco and trade legislation.

From 1976 to 1989, Bill was an attorney with the Public Citizen Litigation Group, where he litigated law reform cases on state and federal constitutional law, antitrust and administrative law, voting rights, product liability, nuclear power, and food and drug law, and where he argued dozens of appellate cases, including several in the U.S. Supreme Court.

  • Serves as an arbitrator in a complex contract matters.
  • Worked extensively on regulations implementing the Affordable Care Act and litigation involving the Act, as well as regulations and litigation related to FDA and other HHS programs.
  • Represented a leading generic manufacturer in congressional negotiations regarding biosimilar legislation.
  • Represented generic manufacturers in navigating the regulatory requirements at FDA.
  • Represented a state in one of the first cases against the makers of OxyContin, helping to secure a large settlement just prior to jury selection.
  • Represented a generic manufacturer that obtained a $3 million payment as compensation for lost profits during a temporary restraining order that prevented the FDA from approving the client’s generic version of a popular allergy drug. Zuckerman Spaeder also represented this client when it prevailed in defeating a motion for a preliminary injunction seeking to stop FDA from approving its generic.
  • Provided expert testimony at hearings on issues related to off-label promotion and cosmetic and drug advertising.
  • Advised the New York City Board of Health on preemption case brought to block implementation of its requirement for labeling in restaurants.
  • Acted as counsel to a state in efforts to facilitate the importation of prescription drugs from Canada.
  • Filed an amicus brief in the U.S. Supreme Court on behalf of Senator Edward M. Kennedy and Congressman Henry A. Waxman regarding preemption of state product liability claims brought in connection with defective medical devices.
  • Represented leading public health group in legislation to give the FDA jurisdiction over tobacco products.
  • Filed an amicus brief in support of the current FDA standards regulating the use of experimental drugs that have not been approved, a position that was upheld in the U.S. Court of Appeals for the District of Columbia Circuit.
  • Represented generic manufacturers seeking generic exclusivity for a popular diabetes drug, a cholesterol lowering agent, and an epilepsy drug.
  • Testified before Congress on legislation involving drug safety and drug imports.

Mentioned & Quoted



Bar Admissions

Court Admissions

Professional Affiliations

  • Leadership Council, Yale School of Public Health
  • Board, Historical Society of the District of Columbia Circuit
  • Member, Committee on Science, Technology & Law, National Academy of Sciences